What lies ahead for vaccines

Podcast

Contemporary Pediatrics sat down with editor-in-chief Dr. Tina Q. Tan to discuss the authorization of the Pfizer/BioNTech vaccine for use in many children as well as what lies ahead in the vaccine pipeline for the pediatric population.

The news about the Pfizer/BioNTech COVID-19 vaccine becoming available for children aged 5 to 11 years was met with happiness by pediatricians and many parents alike. Vaccines in the pipeline could bring similar happiness if found safe and effective.

Contemporary Pediatrics sat down with editor-in-chief Dr. Tina Q. Tan to discuss the authorization of the Pfizer/BioNTech vaccine for use in many children as well as what lies ahead in the vaccine pipeline for the pediatric population.

Recent Videos
Jillian Cotter, MD
Decreasing antibiotics for acute otitis media and community acquired pneumonia, with Elysha Pifko, MD
Tina Tan, MD
Danielle Van Damme, DNP, CPNP-AC
Karen Y. Capusan, DNP, CPNP-PC
Measles outbreaks: 223 cases reported in Texas | Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Tina Tan, MD
Related Content
Maternal RSV vaccine data reveal uptake disparities | Image Credit: © Anna - © Anna - stock.adobe.com.

Maternal RSV vaccine data reveal uptake disparities

Morgan Ebert, Managing Editor
May 20th 2025
Article

These findings come as many health care professionals still report limited confidence and inconsistent practices regarding RSV immunization discussions.

What's going on with polio, monkeypox, and COVID-19

What's going on with polio, monkeypox, and COVID-19

Miranda Hester
August 19th 2022
Podcast

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

RSV data highlight age- and condition-specific risks for severe disease in children | Image Credit: © bankrx - © bankrx - stock.adobe.com.

Age, condition-specific risks for severe RSV disease in children

Joshua Fitch, Senior Editor
May 17th 2025
Article

Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions.

What Omicron could mean for the pandemic

What Omicron could mean for the pandemic

Miranda Hester
January 7th 2022
Podcast

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

Infant RSV hospitalization rates 28%, 43% lower this season vs pre-COVID seasons | Image Credit: © MargJohnsonVA - © MargJohnsonVA - stock.adobe.com.

Infant RSV hospitalization rates 28%, 43% lower this season vs pre-COVID seasons

Joshua Fitch, Senior Editor
May 9th 2025
Article

"These findings support Advisory Committee on Immunization Practices’ recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants," wrote the MMWR study investigators.

RSV prophylaxis: Palivizumab, nirsevimab, and more | Image Credit: © John Doe - © John Doe - stock.adobe.com.

RSV prophylaxis: Palivizumab, nirsevimab, and more

Noah Christian, MD;Joseph M. Collaco, MD, PhD
May 6th 2025
Article

Current prevention strategies include 2 injectables for infants and young children, namely palivizumab and nirsevimab.

© 2025 MJH Life Sciences

All rights reserved.